[1] Stanbury M, Rosenman KD. Occupational health disparities:a state public health based approach. Am J Ind Med, 2014; 57, 596-604. doi:  10.1002/ajim.v57.5
[2] Leung C, Yu I, Chen W. Silicosis. Lancet, 2012; 379, 2008-18. doi:  10.1016/S0140-6736(12)60235-9
[3] Rimal B, Greenberg AK, Rom WN. Basic pathogenetic mechanisms in silicosis:current understanding. Curr Opin Pulm Med, 2005; 11, 169-73. doi:  10.1097/01.mcp.0000152998.11335.24
[4] Wang J, Chen L, Chen B, et al. Chronic Activation of the Renin-Angiotensin System Induces Lung Fibrosis. Sci Rep, 2015; 5, 15561. doi:  10.1038/srep15561
[5] Murphy AM, Wong AL, Bezuhly M. Modulation of angiotensin Ⅱ signaling in the prevention of fibrosis. Fibrogenesis Tissue Repair, 2015; 8, 7. doi:  10.1186/s13069-015-0023-z
[6] Wang M, Chen DQ, Chen L, et al. Novel inhibitors of the cellular RAS components, Poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis. Br J Pharmacol, 2018; 175, 2689-708. doi:  10.1111/bph.v175.13
[7] Chen H, Yang T, Wang MC, et al. Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation. Phytomedicine, 2018; 42, 207-18. doi:  10.1016/j.phymed.2018.03.034
[8] Zielonka TM, Zycinska K, Chorostowska-Wynimko J, et al. Angiogenic activity of sera from interstitial lung disease patients in relation to angiotensin-converting enzyme activity. Adv Exp Med Biol, 2013; 756, 213-21. doi:  10.1007/978-94-007-4549-0
[9] Xu H, Yang F, Sun Y, et al. A new antifibrotic target of Ac-SDKP:inhibition of myofibroblast differentiation in rat lung with silicosis. PLoS One, 2012; 7, e40301. doi:  10.1371/journal.pone.0040301
[10] Uhal BD, Li X, Piasecki CC, et al. Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol, 2012; 44, 465-8. doi:  10.1016/j.biocel.2011.11.019
[11] Fraga-Silva RA, Ferreira AJ, Dos Santos RA. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor pathway in hypertension, Curr Hypertens Rep, 2013; 15, 31-8.
[12] Meng Y, Yu CH, Li W, et al. Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Axis Protects against Lung Fibrosis by Inhibiting the MAPK/NF-κB Pathway. Am J Respir Cell Mol Biol, 2014; 50, 723-36. doi:  10.1165/rcmb.2012-0451OC
[13] Chang Seong Kim, In Jin Kim, Eun Hui Bae, et al. Angiotensin-(1-7) Attenuates Kidney Injury Due to Obstructive Nephropathy in Rats. PLoS One, 2015; 10, e0142664. doi:  10.1371/journal.pone.0142664
[14] Xie H, Lu J, Zhu Y, et al. The KCa3. 1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis. Toxicol Letters, 2018; 295, 408-15. doi:  10.1016/j.toxlet.2018.07.020
[15] Liu Y, Xu H, Geng YC, et al. Dibutyryl-cAMP attenuates pulmonary fibrosis by blocking myofibroblast differentiation via PKA/CREB/CBP signaling in rats with silicosis. Respir Res, 2017; 18, 38. doi:  10.1186/s12931-017-0523-z
[16] Wang CJ, Zhou ZG, Holmqvist A, et al. Survivin expression quantified by Image Pro-Plus compared with visual assessment. Appl Immunohistochem Mol Morphol, 2009; 17, 530-5. doi:  10.1097/PAI.0b013e3181a13bf2
[17] Zhou B, Liu Y, Kahn M, et al. Interactions between beta-catenin and transforming growth factor-beta signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J Biol Chem, 2012; 287, 7026-38. doi:  10.1074/jbc.M111.276311
[18] Tumelty KE, Smith BD, Nugent MA, et al. Aortic carboxypeptidase-like protein (ACLP) enhances lung myofibroblast differentiation through transforming growth factor beta receptor-dependent and -independent pathways. J Biol Chem, 2014; 289, 2526-36. doi:  10.1074/jbc.M113.502617
[19] Ferrario CM. ACE2:more of Ang-(1-7) or less AngⅡ? Curr Opin Nephrol Hypertens, 2011; 20, 1-6. doi:  10.1097/MNH.0b013e3283406f57
[20] Santos RA, Ferreira AJ, Verano-Braga T, et al. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas:new players of the renin-angiotensin system. J Endocrinol, 2013; 216, R1-17.
[21] VinayakShenoy, Qi YF, Michael J Katovich. ACE2, a Promising Therapeutic Target for Pulmonary Hypertension. Curr Opin Pharmacol, 2011; 11, 150-5. doi:  10.1016/j.coph.2010.12.002
[22] Ali Q, Wu Y, Hussain T. Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int, 2013; 84, 931-9. doi:  10.1038/ki.2013.193
[23] Hao PP, Yang JM, Liu YP, et al. Combination of angiotensin-(1-7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy. Sci Rep, 2015; 5, 8794. doi:  10.1038/srep08794